2,030
Views
4
CrossRef citations to date
0
Altmetric
Clinical features - Original research

Effect of a change in lasmiditan dose on efficacy and safety in patients with migraine

ORCID Icon, ORCID Icon, , ORCID Icon, ORCID Icon & ORCID Icon
Pages 449-459 | Received 11 Oct 2020, Accepted 04 Dec 2020, Published online: 17 Mar 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Christopher C Anderson & Juliana H VanderPluym. (2023) Profile of Lasmiditan in the Acute Treatment of Migraine in Adults: Design, Development, and Place in Therapy. Drug Design, Development and Therapy 17, pages 1979-1993.
Read now

Articles from other publishers (3)

Alejandro Labastida-Ramírez, Marco Lisicki, Marcio Nattan Souza, Lucas David Llenas & Sadia Janjua. (2024) Dipyrone for the acute treatment of migraine attacks in children and adults. Cochrane Database of Systematic Reviews 2024:4.
Crossref
Erin G. Doty, Paula M. Hauck, John H. Krege, Mika Komori, Ann M. Hake, Yan Dong & Richard B. Lipton. (2022) The Association Between the Occurrence of Common Treatment-Emergent Adverse Events and Efficacy Outcomes After Lasmiditan Treatment of a Single Migraine Attack: Secondary Analyses from Four Pooled Randomized Clinical Trials. CNS Drugs 36:7, pages 771-783.
Crossref
Yu‐Cong Liu, Ting‐Ting Yang, Jing Li, Hui‐Chan Xu, Shun‐Lian Li & Liu‐Lin Xiong. (2021) Breakthroughs on the clinical management of headache and questions that need to be solved. Ibrain 7:4, pages 298-308.
Crossref